Video
Author(s):
Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.
P1101 Treatment Meets Phase 3 Primary End Point in Essential Thrombocythemia
FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis
Ryoncil Receives FDA Approval for Children With GVHD
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis
CURE Honors Seven Honorees at MPN Heroes Event